IL-1ra/IL-1F3/IL1RN Antibody [Unconjugated]

Recombinant Mouse IL‑1ra/IL‑1F3 (Catalog # 480‑RM) inhibits Recombinant Human IL‑1 alpha /IL‑1F1 (Catalog # 200‑LA) induced proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IL‑1 alpha /IL‑1F1 (50 pg/mL) activity elicited by Recombinant Mouse IL‑1ra/IL‑1F3 (150 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse IL‑1ra/IL‑1F3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-480-NA). The ND50 is typically 1-5 µg/mL.

• Reactivity: Mu
• Applications: WB, B/N, ELISA(Cap)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-1ra/IL-1F3/IL1RN Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse IL‑1ra/IL-1F3
• Specificity: Detects mouse IL-1ra/IL-1F3 in ELISAs and Western blots. In sandwich ELISAs, approximately 45% cross-reactivity with recombinant rat IL‑1ra/IL‑1F3 and less than 1% cross-reactivity with recombinant human IL‑1ra/IL‑1F3, recombinant porcine IL‑1ra/IL‑1F3, and recombinant equine IL‑1ra/IL‑1F3 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL1RN
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 0.2-0.8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 1-5 ug/mL
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture:Mouse IL-1ra/IL-1F3 Antibody (Catalog # AF-480-NA)
  ELISA Detection: Mouse IL-1ra/IL-1F3 Biotinylated Antibody (Catalog # BAF480)
  Standard: Recombinant Mouse IL-1ra/IL-1F3 (Catalog # 480-RM)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-1ra/IL-1F3/IL1RN Antibody [Unconjugated]

• DIRA
• ICIL-1ra
• IL1F3
• IL-1F3
• IL1ra
• IL-1ra
• IL-1ra3
• IL1RN
• IL-1RN
• interleukin 1 receptor antagonist
• IRAP
• MVCD4

Background

IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally-occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha . It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells. In mouse, IL-1 RII does not bind IL-1ra. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Pre-clinical and clinical studies were done to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-1ra/IL-1F3/IL1RN Antibody (AF-480-NA)(13)

Publications using AF-480-NA

• Buchheit, T;Huh, Y;Breglio, A;Bang, S;Xu, J;Matsuoka, Y;Guo, R;Bortsov, A;Reinecke, J;Wehling, P;Jun Huang, T;Ji, RR; Intrathecal Administration of Conditioned Serum from Different Species Resolves Chemotherapy-Induced Neuropathic Pain in Mice via Secretory Exosomes Brain, behavior, and immunity 5/5/2023 [PMID: 37150265]
• Y Zheng, X Dong, S Chen, Y He, J An, M Liu, L He, Y Zhang Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing BMC Oral Health, 2023-01-10;23(1):14. 2023-01-10 [PMID: 36627695] (Neutralization, Mouse)
• CU von Linsto, SM Hindkjær, PV Nielsen, M Degn, KL Lambertsen, B Finsen, BH Clausen Bone Marrow-Derived IL-1Ra Increases TNF Levels Poststroke Cells, 2021-04-20;10(4):. 2021-04-20 [PMID: 33924148] (ICC, Mouse)
• X Lu, JW Horner, E Paul, X Shang, P Troncoso, P Deng, S Jiang, Q Chang, DJ Spring, P Sharma, JA Zebala, DY Maeda, YA Wang, RA DePinho Effective combinatorial immunotherapy for castration-resistant prostate cancer Nature, 2017-03-20;543(7647):728-732. 2017-03-20 [PMID: 28321130] (Neutralization, Mouse)
• Correction: Yersinia pestis Activates Both IL-1beta and IL-1 Receptor Antagonist to Modulate Lung Inflammation during Pneumonic Plague. PLoS Pathog, 2015-05-13;11(5):e1004921. 2015-05-13 [PMID: 25970482] (Mouse)
• Yamato M, Tamura Y, Eguchi A, Kume S, Miyashige Y, Nakano M, Watanabe Y, Kataoka Y Brain interleukin-1beta and the intrinsic receptor antagonist control peripheral Toll-like receptor 3-mediated suppression of spontaneous activity in rats. PLoS ONE, 2014-03-12;9(3):e90950. 2014-03-12 [PMID: 24621600] (Neutralization, Western Blot, Rat)
• Bryce N. Alves, Rachel Tsui, Jonathan Almaden, Maxim N. Shokhirev, Jeremy Davis-Turak, Jessica Fujimoto et al. I kappa B epsilon Is a Key Regulator of B Cell Expansion by Providing Negative Feedback on cRel and RelA in a Stimulus-Specific Manner The Journal of Immunology 4/1/2014 [PMID: 24591377]
• Ilksen Gurkan, Archana Ranganathan, X. Yang, Walter E. Horton, Martin Todman, James Huckle et al. Modification of osteoarthritis in the guinea pig with pulsed low-intensity ultrasound treatment Osteoarthritis and Cartilage 5/1/2010 [PMID: 20175971]
• Osuchowski MF, Connett J, Welch K, Granger J, Remick DG Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit. Care Med., 2009-05-01;37(5):1567-73. 2009-05-01 [PMID: 19325479] (ELISA Development, Mouse)
• Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc. Natl. Acad. Sci. U.S.A., 2007-06-14;104(26):11002-7. 2007-06-14 [PMID: 17569781] (Neutralization, Mouse)
• Osuchowski MF, Welch K, Siddiqui J, Remick DG Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J. Immunol., 2006-08-01;177(3):1967-74. 2006-08-01 [PMID: 16849510] (ELISA Development, Mouse)
• Osuchowski MF, Siddiqui J, Copeland S, Remick DG Sequential ELISA to profile multiple cytokines from small volumes. J. Immunol. Methods, 2005-07-01;302(1):172-81. 2005-07-01 [PMID: 16023134] (ELISA Development, Mouse)
• Park EM, Cho BP, Volpe BT, Cruz MO, Joh TH, Cho S Ibuprofen protects ischemia-induced neuronal injury via up-regulating interleukin-1 receptor antagonist expression. Neuroscience, 2005-01-01;132(3):625-31. 2005-01-01 [PMID: 15837124] (IHC-Fr, Neutralization, Rat)

Bioinformatics

• Gene Symbol: IL1RN